A phase I study comparing the safety, pharmacokinetics, and pharmacodynamics of infliximab administered by the subcutaneous, intravenous followed by subcutaneous, or intramuscular routes of administration in rheumatoid arthritis patients.

Westhovens, R., Durez, P., Hollssiau, F., Daniel, E., Bouman-Thio, E., Sisco, D., van Hartingsveldt, B., Mascelli, M., Zhu, Y., Graham, M., & Joly, J. (2004). A phase I study comparing the safety, pharmacokinetics, and pharmacodynamics of infliximab administered by the subcutaneous, intravenous followed by subcutaneous, or intramuscular routes of administration in rheumatoid arthritis patients. Arthritis & Rheumatism, 50(9), S179-S179. https://hdl.handle.net/2078.5/140726 (Original work published 2004)